Skip to Content
VaccinesVaccines
  • Article
  • Open Access

5 February 2015

16 Pages

EBV-Associated Cancer and Autoimmunity: Searching for Therapies

,
,
,
and
1
Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari 70126, Italy
2
Brain and Language Laboratory, Free University of Berlin, 14195 Berlin, Germany
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Cancer Vaccines

Abstract

Epstein-Barr virus (EBV) infects B-, T-, and NK cells and has been associated not only with a wide range of lymphoid malignancies but also with autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and, in particular, multiple sclerosis. Hence, effective immunotherapeutic approaches to eradicate EBV infection might overthrow cancer and autoimmunity incidence. However, currently no effective anti-EBV immunotherapy is available. Here we use the concept that protein immunogenicity is allocated in rare peptide sequences and search the Epstein-Barr nuclear antigen 1 (EBNA1) sequence for peptides unique to the viral protein and absent in the human host. We report on a set of unique EBV EBNA1 peptides that might be used in designing peptide-based therapies able to specifically hitting the virus or neutralizing pathogenic autoantibodies.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.